Joe Loy

Joe Loy is the President and CEO of Zetagen Therapeutics, a Syracuse, New York clinical-stage biopharmaceutical company developing small-molecule therapies to treat metastatic cancer in bone and soft tissue while regenerating healthy bone. A serial entrepreneur with several successful exits, Loy has spent his career building teams around first-to-market medical technologies at companies including US Surgical, Pfizer/Leibinger, NuVasive, and Stryker. Since taking the helm in January 2019, he has guided Zetagen through two FDA Breakthrough Device Designations, multiple financing rounds, and the launch of Phase 2a clinical trials for its lead candidate ZetaMet.